Clinical Trial: Pharmacogenetic Study of Obsessive-Compulsive Disorder

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Pharmacogenetic Study of Obsessive-Compulsive Disorder

Brief Summary: The purpose of this study is to determine whether pharmacogenetic study predict selective serotonin reuptake inhibitor (SSRI) responsiveness in advance before the appearance of the drug effect until 4 months(16 weeks), 6 months, and 1 year after administration of SSRIs.

Detailed Summary:

The purpose of this study is to determine the effects of genetic variants on the response to SSRIs in obsessive-compulsive disorder (OCD) subject.

The investigators will recruit drug-naive or drug-free(> 3 months) OCD subjects (n=200). The participants will get SSRIs for their OCD symptoms. The type and dose of SSRIs will not be restricted and will depend on the individual participant's state. However, the investigators will be recommended to follow usual clinical guideline (the Korean treatment algorithm for OCD, 2004). At baseline, 4 month, 6 months, and 1 year after treatment, the participants will be evaluated by Yale-Brown Obsessive-Compulsive Scale(YBOCS), Montgomery Asberg Depression Rating Scale(MADRS), Dimensional Obsessive-Compulsive Scale(DOCS), Toronto alexithymia scale (TAS), interpersonal reactivity index (IRI), Barratt impulsiveness scale (BIS), and the Measure of Constructs Underlying Perfectionism(M-CUP).

And all the participants will donate 5 ml of whole blood and DNA will be extracted.

Using various genetic analyses methods such as genotyping, exome sequencing, and so on we will analyze the association of various genetic variants and the anti-obsessive-compulsive responses.


Sponsor: Severance Hospital

Current Primary Outcome: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale [ Time Frame: baseline, 4 months, 6 months, 1 year ]

rating scale for obsessive-compulsive symptom severity consisting of 10 items


Original Primary Outcome: Change from baseline in the Yale-Brown Obsessive-Compulsive Scale [ Time Frame: baseline, 4 months, 6 months, 1 year ]

Current Secondary Outcome:

  • Change from the baseline Montgomery-Asberg Depression Rating Scale [ Time Frame: baseline, 4 months, 6 months, 1 year ]
    rating scale for depressive symptom severity consisting of 10 items
  • Occurrence of any side effects during the SSRIs treatment [ Time Frame: 4 months, 6 months, 1 year ]
    any adverse events related to SSRI use


Original Secondary Outcome:

  • Change from the baseline Montgomery-Asberg Depression Rating Scale [ Time Frame: baseline, 4 months, 6 months, 1 year ]
  • Occurrence of any side effects during the SSRIs treatment [ Time Frame: 4 months, 6 months, 1 year ]


Information By: Severance Hospital

Dates:
Date Received: April 23, 2015
Date Started: January 2013
Date Completion: June 2019
Last Updated: April 24, 2017
Last Verified: April 2017